120 likes | 128 Views
According to Coherent Market Insights, Cell imaging and analysis equipment segment in the global high content screening (HCS) market is expected to exhibit a CAGR of 5.8%% during the forecast period 2020-2027.
E N D
Coherent Market Insights Market Research and Business Consulting Services https://www.coherentmarketinsights.com/ COVID-19 Impact Tracker
HIGH CONTENT SCREENING MARKET ANALYSIS High Content Screening Market,ByProduct Type (Cell Imaging and Analysis Equipment, Consumables, HCS Software, HCS Services), By Application (Primary Screening, Target Identification & Validation, Toxicity Studies, Compound Profiling, Others), By End User (Pharmaceutical Organizations, Biotechnology Organizations, Research Institutes, Independent CRO, Government Organizations, Others), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, Africa) - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027
The global high content screening (HCS) market is estimated to account for US$ 1,404.6 Mn in terms of value in 2018 and is expected to reach US$ 2,387.9 by the end of 2027. Drivers • R&D in drug discovery is expected to propel growth of the global high content screening (HCS) market over the forecast period.Forinstance, in February 2020,researchers from Purdue University reported assessment of the effects of IL-27 – a heterodimeric cytokine composed of subunits IL-27p28 and EBI3 (Epstein–Barr virus-induced gene 3) – on the gene expression changes of TC2R prostate adenocarcinoma cells. • Moreover,increasinginvestment in HCS is expected to aid in growth of the market.Forinstance,inJanuary 2020, St. Jude Children’s Research Hospital invested US$ 13.4 million for building a laboratory resource center,whichwill include two new labs,theCenter for Modeling Human Pediatric Diseases and High Content Screening. • North America region held dominant position in the global high content screening (HCS) market in 2018,accounting for 36.4% share in terms of value, followed by Europe.
Market Restraints • Image analysis for HCS is a time-consuming and labor-intensive process, which is expected to hinder growth of the market. • Moreover,lackof budget for high-end HCS instruments in emerging economies is expected to hamper growth of the market. • Cell imaging and analysis equipment segment in the global high content screening (HCS) market was valued at US$ 550.1 Mn in 2018 and is expected to reach US$ 911.3 Mn by 2027 at a CAGR of 5.8% during the forecast period.
Market Trends • The market is witnessing use of Artificial Intelligence (AI) in HCS. Use of automation offers rapid detection of all cellular phenotypes in an HCS. It can also reduce the time and costs required for phenotypic image analysis. For instance, in December 2019, Olympus launched the scanR HCS station, a cell imaging solution that utilizes AI to enable next-generation biological research. • HCS is being used for development of an automated imaging pipeline. For instance, in March 2019, researchers from Digital Biomedical Imaging Systems AG reported processing and analysis of HCS datasets using custom-developed heuristic algorithms implemented in common open-source image analysis software to identify chemical modifiers of glomerular cyst formation in a zebrafish model for human cystic kidney disease.
Competitive Section Major players operating in the global high content screening (HCS) market include, Becton, Dickinson and Company, Thermo Fisher Scientific Inc., GE Healthcare, Olympus Corporation, PerkinElmer Inc., Merck Millipore Corporation, Danaher Corporation (Molecular Devices), Yokogawa Electric Corporation, Sysmex Corporation, and Thorlabs, Inc.
Key Developments • Major players in the market are focused on launching new products to expand their product portfolio. For instance, in January 2020, PerkinElmer, Inc. launched new workstations and Opera Phenix Plus High Content Screening System at SLAS2020 International Conference and Exhibition, held in California. • Major players in the market are also focused on adopting collaboration and partnership strategies to expand their product portfolio. For instance, in December 2019, GE Healthcare Life Sciences entered into a strategic R&D and distribution partnership with Advanced Solutions Life Sciences under which BioAssemblyBot will be integrated with IN Cell Analyzer 6500 HS confocal screening platform in order to automate HCS in 3D models, for personalized tissue regeneration.
Request Sample Report • Request Customization • Download PDF Brochure • Talk to Analyst Reference: https://www.coherentmarketinsights.com/market-insight/high-content-screening-market-3487
About Us Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. What we provide: • Customized Market Research Services • Industry Analysis Services • Business Consulting Services • Market Intelligence Services • Long term Engagement Model • Country Specific Analysis
Contact Us Mr. Shah Coherent Market Insights Pvt.Ltd. Address: 1001 4th Ave, #3200 Seattle, WA 98154, U.S. Phone: +1-206-701-6702 Email: sales@coherentmarketinsights.com
Thank You! Kindly follow CMI Social Media Profiles for the latest company updates Facebook Linkedin Twitter https://www.coherentmarketinsights.com/